<DOC>
	<DOCNO>NCT00035971</DOCNO>
	<brief_summary>The purpose study determine treatment raloxifene compare treatment alendronate postmenopausal woman osteoporosis chance experiencing fracture</brief_summary>
	<brief_title>EVA : Evista Alendronate Comparison</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria 5080 year age , inclusive 2 year since last menses Dx femoral neck osteoporosis No vertebral fracture Exclusion Criteria Poor candidate study drug Hx diseases affect bone metabolism Hx breast/estrogendependent cancer Current use osteoporosis drug therapy Hx/high risk VTE</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>